DCM
OBIO icon

DAFNA Capital Management’s Orchestra BioMed OBIO Stock Holding History

DAFNA Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$547K Hold
126,841
– – 0.1% 75
2026
Q1 		$539K Hold
126,841
– – 0.12% 76
2025
Q4 		$526K Sell
126,841
-236,795
-65% -$955K 0.12% 69
2025
Q3 		$902K Buy
+363,636
New +$1M 0.22% 59

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

DAFNA Capital Management's OBIO Position: Q2 2026 in Review

DAFNA Capital Management held its Orchestra BioMed (OBIO) position steady in Q2 2026 at 126,841 shares worth $547K. The position accounts for 0.1% of the portfolio, ranked #75.

DAFNA Capital Management first reported a position in OBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $902K in Q3 2025. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • DAFNA Capital Management held 126,841 shares of Orchestra BioMed worth $547K as of Q2 2026.
  • DAFNA Capital Management left its Orchestra BioMed share count unchanged in Q2 2026.
  • Orchestra BioMed made up 0.1% of DAFNA Capital Management's portfolio in Q2 2026, its #75 holding.
  • DAFNA Capital Management first reported a position in Orchestra BioMed in Q3 2025 and has held it in 4 quarters since.
  • DAFNA Capital Management's Orchestra BioMed position peaked at $902K in Q3 2025.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.